TY - JOUR
T1 - Ten years of HPV vaccination in the Netherlands
T2 - current evidence and future challenges in HPV-related disease prevention
AU - Qendri, V.
AU - Schurink-van ’t Klooster, T. M.
AU - Bogaards, J. A.
AU - Berkhof, J.
PY - 2018/12/2
Y1 - 2018/12/2
N2 - Introduction: Girls-only vaccination against human papillomavirus (HPV) type 16 and 18 was implemented in the Netherlands in 2009. Despite the evidence of the efficacy against precancerous lesions, cross-protection induced by the vaccine and a greater potential for cancer prevention than cervical cancer only, vaccine coverage in the girls-only program has remained below target levels. Areas covered: In this paper, we review the literature from the Netherlands on the effectiveness and cost-effectiveness of HPV vaccination since vaccine introduction, give an account of the coverage, safety and effectiveness of HPV vaccination as has been reported in the Dutch surveillance program and discuss challenges of the current HPV vaccination program. Expert commentary: Girls-only HPV vaccination may confer a substantial health gain in HPV-related disease prevention. However, vaccine coverage declined remarkably recently possibly related to safety concerns, limiting the benefits from girls’ vaccination and increasing the potential additional benefit of sex-neutral HPV vaccination. Considering the emergence of novel vaccination and screening options and the change from cytology- to HPV-based screening in 2017, further research is required to inform decisions on the optimization of an integrated vaccination and screening program.
AB - Introduction: Girls-only vaccination against human papillomavirus (HPV) type 16 and 18 was implemented in the Netherlands in 2009. Despite the evidence of the efficacy against precancerous lesions, cross-protection induced by the vaccine and a greater potential for cancer prevention than cervical cancer only, vaccine coverage in the girls-only program has remained below target levels. Areas covered: In this paper, we review the literature from the Netherlands on the effectiveness and cost-effectiveness of HPV vaccination since vaccine introduction, give an account of the coverage, safety and effectiveness of HPV vaccination as has been reported in the Dutch surveillance program and discuss challenges of the current HPV vaccination program. Expert commentary: Girls-only HPV vaccination may confer a substantial health gain in HPV-related disease prevention. However, vaccine coverage declined remarkably recently possibly related to safety concerns, limiting the benefits from girls’ vaccination and increasing the potential additional benefit of sex-neutral HPV vaccination. Considering the emergence of novel vaccination and screening options and the change from cytology- to HPV-based screening in 2017, further research is required to inform decisions on the optimization of an integrated vaccination and screening program.
KW - HPV vaccines
KW - Human papillomavirus
KW - Netherlands
KW - cost-effectiveness
KW - coverage
KW - effectiveness
KW - national immunization program
KW - safety
KW - surveillance
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85058596386&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30417704
UR - http://www.scopus.com/inward/record.url?scp=85058596386&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/14760584.2018.1547196
DO - https://doi.org/10.1080/14760584.2018.1547196
M3 - Review article
C2 - 30417704
SN - 1476-0584
VL - 17
SP - 1093
EP - 1104
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 12
ER -